Health news round-up: contraception, obesity inequalities and eating disorders on GLP-1s. The Pharmaceutical Journal’s weekly summary of the important developments in pharmacy and health news you may have missed. This week, The Pharmaceutical Journal has reported on a drug to delay symptoms of type 1 diabetes mellitus, detail about the community pharmacy meningitis B vaccination campaign, renewed discussion around ‘excessive’ pricing of an epilepsy drug, a minimum age set for  the ‘PATHWAYS’ puberty blockers trial, and a successful smoking cessation clinic led by pharmacists and dentists that resulted in a 20% quit rate. Read on for more health news you may have missed this week. This week, the National Institute for Health and Care Excellence recommended cemiplimab (Libtayo; Regeneron) as an option for adults with recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy. In addition, NICE recommended pembrolizumab, which was already recommended for persistent, recurrent or metastatic cervical cancer, for use earlier in the disease pathway as a routine first-line treatment option for adults with untreated locally advanced cervical cancer.

Health news round-up: contraception, obesity inequalities and eating disorders on GLP-1s

The Pharmaceutical Journal presents its weekly recap of significant pharmacy and health news that may have escaped your attention. This week's coverage includes information on a medication designed to postpone the onset of type 1 diabetes mellitus, specifics regarding the meningitis B vaccination initiative within community pharmacies, a resurgence of debate concerning the 'excessive' cost of an epilepsy medication, the establishment of a minimum age for the 'PATHWAYS' puberty blockers study, and a highly effective smoking cessation program, operated by pharmacists and dentists, which achieved a 20% success rate in helping individuals quit smoking. Continue reading for additional health news from the past week.

Furthermore, the National Institute for Health and Care Excellence (NICE) has endorsed cemiplimab (Libtayo; Regeneron) as a potential treatment for adults diagnosed with recurrent or metastatic cervical cancer that has not responded to or has worsened following platinum-based chemotherapy. Concurrently, NICE has also approved pembrolizumab for earlier application in the treatment regimen. This drug, previously sanctioned for persistent, recurrent, or metastatic cervical cancer, will now be available as a standard initial treatment option for adult patients with untreated, locally advanced cervical cancer.